EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned

Sarah A Jones, Eric F Morand

Drugs · 2024

DOI: 10.1007/s40265-024-02043-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Sarah A Jones und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammatory Disease, Monash University, Clayton, Australia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Signal Transduction. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Lupus Research Alliance, Open Access funding enabled and organized by CAUL and its Member Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only three drugs receiving regulatory approval for SLE in the last 60 years, one of which was specifically licensed for lupus nephritis. In the last 20 years it has become clear that activation of type 1 interferons (IFN) is reproducibly detected in the majority of SLE patients, and the actions of IFN in the immune system and on target tissues is consistent with a pathogenic role in SLE. These findings led to considerable drug discovery activity, first with agents directly targeting IFN family cytokines, with results that were encouraging but underwhelming. In contrast, targeting the type I IFN receptor with the monoclonal antibody anifrolumab, thereby blocking all IFN family members, was effective in a phase II clinical trial. This led to a pair of phase III trials, one of which was negative and the other positive, reflecting the difficulty of obtaining outcomes from trials in this complex disease. Nonetheless, the balance of evidence resulted in approval of anifrolumab in multiple jurisdictions from 2021 onwards. Multiple approaches to targeting the type 1 IFN pathway have subsequently had positive phase II clinical trials, including antibodies targeting cells that produce IFN, and small molecules targeting the receptor kinase TYK2, required for IFN signalling. Despite multiple hurdles, it is clear that IFN targeting in SLE is here to stay. The story of IFN-targeting therapy in SLE has lessons for drug development overall in this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicSignal TransductionHumansAntibodies, Monoclonal, HumanizedInterferon Type IInterferonsAntibodies, Monoclonal

Substanzen

anifrolumabAntibodies, Monoclonal, HumanizedInterferon Type IInterferonsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Centre for Inflammatory Disease, Monash University, Clayton, Australia.
  • Centre for Inflammatory Disease, Monash University, Clayton, Australia. eric.morand@monash.edu.
  • Department of Rheumatology, Monash Health, Melbourne, Australia. eric.morand@monash.edu.
  • Monash Medical Centre, 246 Clayton Rd, Clayton, VIC, 3168, Australia. eric.morand@monash.edu.

Förderung

  • National Health and Medical Research Council
  • Lupus Research Alliance
  • Open Access funding enabled and organized by CAUL and its Member Institutions
  • Monash University

Zitieren

APA

Jones, S. A., & Morand, E. F. (2024). Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Drugs. https://doi.org/10.1007/s40265-024-02043-2

Vancouver

Jones SA, Morand EF. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Drugs. 2024. doi:10.1007/s40265-024-02043-2

BibTeX
@article{Jones2024,
  author = {Jones, Sarah A and Morand, Eric F},
  title = {Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02043-2}
}
Kostenlos starten →